Cerebrospinal fluid alpha-synuclein and Lewy-body like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease

Manuscript Number: 

14-1287R2

Author(s): 
Douglas Galasko, Philip Insel, R. Scott Mackin, Niklas Mattsson, Brian Mohlenhoff, Michael W. Weiner, Jing Zhang

Disclosures

Douglas Galasko

  • Nothing to Disclose

Philip Insel

  • Nothing to Disclose

R. Scott Mackin

  • Nothing to Disclose

Niklas Mattsson

  • Nothing to Disclose

Brian Mohlenhoff

  • Nothing to Disclose

Michael W. Weiner

  • Consulting Fees:
    Advisory Boards: 2012 Pfizer Eli Lilly 2013 Pfizer Eli Lilly 2014 Neurotrope Bioscience Consulting: 2012 Harvard University KLJ Associates University of California, Los Angeles (UCLA) Alzheimerâ̢��_��̢��_�s Drug Discovery Foundation (ADDF) 2013 Alzheimerâ̢��_��̢��_�s Drug Discovery Foundation (ADDF) Avid RadioPharmaceuticals Eli Lilly & Co. Clearview Healthcare Partners Perceptive Informatics Smartfish AS Decision Resources, Inc. Araclon Synarc Merck Genentech Defined Health 2014 GroupH, UK
    Lecture Fees:
    2014 Neuroptope Bioscience

Jing Zhang

  • Nothing to Disclose